Schedule 13G ownership disclosure

Kyverna Therapeutics, Inc.

Common Stock, $0.00001 par value per share · CUSIP: 501976104

Event date: 2025-12-31

Filing-level shares
3,110,000
Percent of class
5.4%
  • Bain Capital Life Sciences Opportunities III, LP

    Shares: 3,110,000 · Class: 5.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-054806
Form type
SCHEDULE 13G/A
Filer
Bain Capital Life Sciences Opportunities III, LP
CIK
CIK 1950105
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub